ILMN(ILMN)
ILMN
9/28/26
Illumina (ILMN)
Monday
4:58 PM
ThesisIllumina: the story is balanced — Consumable revenue growth and instrument utilization rates (pull-through per instrument)…
Revenue Outlook
What Moves the Stock
- 01Consumable revenue growth and instrument utilization rates (pull-through per instrument), indicating installed base productivity and end-market demand strength
- 02NovaSeq X adoption trajectory and competitive positioning against emerging long-read sequencing technologies (PacBio, Oxford Nanopore)
- 03Clinical diagnostics revenue growth, particularly multi-cancer early detection tests and liquid biopsy adoption rates in oncology
- 04Regulatory developments affecting genomic testing reimbursement (FDA oversight of laboratory-developed tests, CMS coverage decisions)
- 05China revenue exposure (historically 15-20% of sales) and geopolitical risks affecting instrument exports and consumable demand
- 06Consumables (reagents, flow cells, library prep kits): approximately 65-70% of revenue, recurring high-margin sales tied to installed base utilization
- 07Sequencing instruments (NovaSeq X, NextSeq 2000): approximately 20-25% of revenue, capital equipment sales with 3-5 year replacement cycles
- 08Services and other (maintenance contracts, array products): approximately 10-15% of revenue
FY2025 Snapshot
- Revenue
- $4.3B
- Rev. Growth
- -0.8%
- Gross Margin
- 66.7%
- Op. Margin
- 19.9%
- Net Margin
- 19.6%
- Net Income
- $850M
- NI Growth
- +170%
- EPS
- $5.48
- 1Y Return
- +192%
ILMN Chart
My Notes
- growth - Illumina attracts investors seeking exposure to the structural growth of genomics applications across precision medicine…
- Rising interest rates negatively impact Illumina through two channels: (1) biotech/pharma customers face higher capital costs…
- Watch on earnings: NovaSeq X instrument placements per quarter and consumable pull-through rates (revenue per instrument annually), Clinical diagnostics revenue growth rate and oncology testing partnership announcements (GRAIL separation impact), China revenue trends and geographic diversification progress amid geopolitical tensions.
One Sentence Summary:
Illumina: the story is balanced — consumable revenue growth and instrument utilization rates (pull-through per instrument).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers